comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 02:09:16 - browse：7

Methadone and buprenorphine, both FDA-approved drugs, are considered the gold standard for treating opioid use disorder. They are so effective, in fact, that they are considered nearly curative for people who use them as prescribed. But a multitude of social and physical barriers to access mean that only about 20% of people who could benefit from these medicines have access to them. Access is even harder for pregnant people, who face additional stigmas and challenges.

Arthur Robin Williams, an addiction psychiatrist, and Judith Cole, a nurse practitioner, join the podcast this week to speak about the challenges during pregnancy, including the reality that federal law makes it possible for child protective services to be called when people receiving legal effective treatments for addiction give birth. Despite medications like methadone being fully safe during pregnancy, they continue to carry a stigma that can result in trauma for both birth parents and newborns.

“What’s getting conflated here is a result on a drug test, for instance, with actual abuse or neglect,” said Williams.

Williams and Cole wrote about this issue in their recent First Opinion essay, “Mothers in treatment for opioid use disorder shouldn’t also have to fight child protective services.” You can read more about barriers to addiction treatment in STAT reporter Lev Facher’s series “The War on Recovery.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： 30 years of 'Listening to Prozac'

Wikipedia

focus

WSS

With clinical trial data readouts, here's how to spot spin

Fetal surgery at risk from Dobbs and new abortion restrictions

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Despite FDA concern, risk that CAR

UnitedHealth’s Optum accused of antitrust violations in California

What to expect at HLTH 2023, the health care industry conference

focus

comprehensive

focus

Hepatitis C has a cure — but many Americans still lack access to it

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Jerome Adams on the need for new antivirals for Covid

Why age limits for politicians are a terrible idea

Bright Health sells Medicare Advantage business to Molina

Why age limits for politicians are a terrible idea

The cancer drug shortage isn’t new — and neither are the solutions

Bill would stop addiction treatment from triggering child abuse inquiry

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Fetal surgery at risk from Dobbs and new abortion restrictions

entertainment

FDA panel signals lack of confidence in Amgen cancer drug data

Histogen: Failed biotech offers rare public look inside

Sana to lay off nearly a third of staff, de

Sana to lay off nearly a third of staff, de

Colorectal cancer study finds potential in overlooked immune cell

Histogen: Failed biotech offers rare public look inside

Wikipedia

focus

Wikipedia

focus